Detalles de la búsqueda
1.
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood
; 139(15): 2347-2354, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35108372
2.
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Blood
; 133(13): 1457-1464, 2019 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30630862
3.
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Br J Haematol
; 190(3): 385-393, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32150297
4.
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Blood
; 129(12): 1636-1645, 2017 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28049642
5.
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
Haematologica
; 104(11): 2265-2273, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30948492
6.
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.
Blood
; 125(3): 449-56, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25398935
7.
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Haematologica
; 100(5): 677-82, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25661441
8.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Blood
; 119(26): 6219-25; quiz 6399, 2012 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-22442350
9.
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).
Blood
; 120(24): 4706-11, 2012 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23047822
10.
MMpowerment: Empowering patients with multiple myeloma for shared decision-making by developing an intervention to integrate personal preferences into digital care pathways.
Z Evid Fortbild Qual Gesundhwes
; 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789345
11.
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.
Cancer Med
; 13(9): e6756, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38680089
12.
Why real world outcome information is indispensable in making treatment decisions for multiple myeloma.
Z Evid Fortbild Qual Gesundhwes
; 176: 42-50, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36464588
13.
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Blood
; 115(6): 1113-20, 2010 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-19880501
14.
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Blood Adv
; 6(4): 1115-1125, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34883506
15.
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol
; 155(5): 599-606, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21981697
16.
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Haematologica
; 101(4): e149-52, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26659914
17.
A functional spleen contributes to afucosylated IgG in humans.
Sci Rep
; 11(1): 24045, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34911982
18.
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Blood Adv
; 5(4): 1110-1121, 2021 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616652
19.
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Haematologica
; 100(12): e508-10, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26341740
20.
Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.
Haematologica
; 100(3): e90-2, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25425692